A Topical Peptide Spray Beat Placebo in a 348-Patient Burn Trial

A 26-amino-acid peptide sprayed onto infected burn wounds healed them completely by day 15 in 64.3% of patients, against 43.1% on placebo, in a 348-person randomized trial published this month in Burns & Trauma — and researchers reported finding no trace of the peptide in patients' blood at all.

The peptide, called PL-5 (also known as peceleganan), is a synthetic antimicrobial peptide designed to kill bacteria by punching holes in their cell membranes rather than blocking a single enzyme or receptor, the way most antibiotics do. That mechanism is the whole premise behind the current wave of interest in antimicrobial peptides as a hedge against drug resistance — an earlier Journal post looked at a 160-million-year-old version of the same idea. PL-5 is one of the few to reach a large, placebo-controlled human trial.

What the trial actually tested

The Phase IIIb trial, run at 23 centers in China and registered at ChiCTR2300071255, enrolled adults aged 18 to 65 with infected burns covering up to 10% of body surface area and a confirmed positive bacterial culture. Researchers randomized 348 patients 2:1 to a 2‰ PL-5 spray (232 patients) or an identical-looking placebo spray (116 patients), applied once daily for 14 days.

Burn wounds are a hard environment for any antimicrobial to work in: dead tissue, disrupted blood supply and a mix of bacterial species make topical treatments harder to evaluate than, say, a single-pathogen skin infection. That is part of why researchers ran laboratory testing alongside the clinical trial, measuring PL-5's minimum inhibitory concentration against nine common wound pathogens separately from the patient outcomes, rather than relying on clinical healing rates alone to make the case for the mechanism.

The primary endpoint was complete wound healing by day 15: 64.3% on PL-5 versus 43.1% on placebo (p = 0.0002), a gap researchers said corresponds to a number needed to treat of about 5 — meaning roughly one in five patients healed because of the drug who would not have on placebo alone. By day 21 the gap had narrowed somewhat, to 73.5% versus 56.9%. Researchers also reported better microbiological clearance (72.3% versus 50.5%) and a composite "comprehensive efficacy" measure (63.1% versus 41.9%) favoring PL-5, with laboratory testing showing activity against nine common wound pathogens including Staphylococcus aureus.

On safety, researchers reported similar adverse-event rates between the two groups, no drug-related serious adverse events, and no deaths. Blood tests found PL-5 levels below the limit of quantification in treated patients — in plain terms, the peptide stayed on the wound rather than circulating through the body, which is the result researchers were hoping for in a topical antimicrobial meant to act locally.

What's established versus what's still open

This is a real strength for PL-5's evidence base: a prospective, randomized, double-blind, placebo-controlled trial of this size is uncommon for a topical antimicrobial peptide, and the trial was pre-registered with a defined primary endpoint rather than reported after the fact. The authors, whose group includes researchers at Shenzhen's First Affiliated Hospital of Shenzhen University and Shenzhen Second People's Hospital along with scientists from Jiangsu Protelight Pharmaceutical, which is developing PL-5, said in their discussion that the undetectable blood levels support further study and that the day-15 healing advantage is "clinically meaningful," according to both the published trial and independent coverage by News-Medical.Net.

What the trial does not establish is broader use. It enrolled only mild infections — burns under 10% of body surface area in otherwise healthy working-age adults — and followed patients for just 15 days of primary assessment, so researchers have no data yet on recurrence, resistance developing over repeated use, or performance in more severe, surgical or chronic wounds. Earlier, smaller studies reportedly found PL-5 performed better than the standard topical treatment, silver sulfadiazine cream, but this trial was the first to test it against a placebo rather than an active comparator, which is a higher bar. The authors themselves wrote that the results "do not yet justify replacing standard care in all burn patients," and said a Phase IV study is planned. Readers should also weigh that the company developing PL-5 contributed authors to the trial — not unusual for drug trials, but worth noting when reading the conclusions.

What this means for researchers

The PL-5 trial is a data point in a bigger question researchers in the antimicrobial-peptide field have been trying to answer for years: can a peptide that kills bacteria by physically disrupting their membranes, rather than hitting one molecular target, actually clear an infection in people as reliably as it does in a petri dish? A placebo-controlled, 348-patient result with a clean safety signal and no detectable systemic absorption is a meaningfully stronger answer than the lab and small-cohort data that has carried most antimicrobial peptide research so far.

It's also a narrow answer. The trial speaks to mild, topical burn infections in adults — not to oral or injectable antimicrobial peptides, not to severe or chronic wounds, and not to whether resistance to membrane-disrupting peptides could still emerge with wider or longer use, a question researchers in the field have flagged as unresolved for the whole peptide-antibiotic class. Where PL-5 or similar peptides end up fitting into wound care, if at all, depends on the Phase IV follow-up the authors say is planned, and on whether other groups can replicate a placebo-controlled result at this scale.

For a field that still mostly runs on animal models and single-digit patient counts, a trial this size clearing its primary endpoint is the kind of groundwork that gets Phase IV studies written, not the kind that changes anyone's wound-care instructions on its own.

Torrey Labs publishes certificates of analysis for the compounds it supplies and a general peptide reference guide; this post is reporting on third-party clinical research, not describing anything sold on this site.